GlassScriptPhysician profile
Jayashree T Gowda
NPI 1811334485
$3,221.56
in general payments reported to CMS, 2019-2025
30 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $323 · 2021: $309 · 2022: $792 · 2023: $781 · 2024: $391 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $386.44 | 2019-2025 | Tepezza, Evenity, Prolia |
| Novo Nordisk INC | $344.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $321.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $281.92 | 2021-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $249.76 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $210.16 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.36 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $176.00 | 2020-2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $113.71 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $109.88 | 2023 | Tepezza |
| Corcept Therapeutics | $109.77 | 2019-2023 | Korlym |
| Abbvie INC. | $97.57 | 2020-2025 | |
| Mannkind Corporation | $75.24 | 2022-2023 | Afrezza |
| Merck Sharp & Dohme LLC | $69.85 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $54.89 | 2021-2025 | Gvoke Hypopen |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $47.19 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $47.09 | 2023-2024 | |
| Antares Pharma, INC. | $45.46 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $43.63 | 2023-2025 | |
| Medtronic, INC. | $36.92 | 2023 | Minimed 780g |
| Madrigal Pharmaceuticals | $30.30 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $28.58 | 2025 | Qutenza |
| Insulet Corporation | $28.22 | 2022-2024 | Omnipod |
| Almatica Pharma LLC | $24.07 | 2025 | Teriparatide |
| Beta Bionics, INC. | $22.74 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $22.28 | 2025 | Yorvipath |
| Amryt Pharma Holdings LTD | $18.19 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.78 | 2020 | |
| Bigfoot Biomedical INC | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayashree Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.